Rybelsus (oral semaglutide) for type 2 diabetes: what the video likely gets right and wrong

What did @jomsihatdenganhani actually say?

The transcript provided is garbled and does not reflect the caption's educational claims about Rybelsus. Based on the video caption, the creator walks viewers through what Rybelsus (oral semaglutide) is, how it works, and how to take it correctly. The caption states Rybelsus is "untuk Diabetes Mellitus Type 2" (for type 2 diabetes), describes semaglutide lowering blood sugar and stimulating insulin release from the pancreas, and emphasizes taking it once daily in the morning before food. These are the claims we can evaluate. The spoken transcript, however, is unusable and cannot be fact-checked on its own terms.

It is worth noting upfront: the caption content is largely accurate and responsible in tone. The creator is not pushing weight loss hacks or selling anything obvious. That said, a few important nuances are missing from the summary that patients genuinely need to know before starting this medication.

Does the science back this up?

Yes, the core pharmacology described in the caption is correct, and the clinical evidence for oral semaglutide in type 2 diabetes is solid. The PIONEER trial program, a series of ten phase 3 trials published between 2019 and 2021, established that oral semaglutide (3 mg, 7 mg, and 14 mg doses) reduces HbA1c and fasting plasma glucose significantly compared to placebo and several active comparators.

Aroda et al. (2019, The Lancet) found that oral semaglutide 14 mg reduced HbA1c by 1.4 percentage points versus 0.9 percentage points for empagliflozin over 26 weeks. The mechanism described, specifically that semaglutide stimulates glucose-dependent insulin secretion from pancreatic beta cells, is accurate. Crucially, "glucose-dependent" means insulin release only happens when blood sugar is elevated, which is why hypoglycemia risk is lower than with sulfonylureas. The caption does not explain this nuance, which is a gap worth addressing.

What did they get wrong (or right)?

They got the basics right. Rybelsus does lower blood glucose and does stimulate insulin release in a glucose-dependent manner. The morning dosing instruction is also correct and clinically important. Rybelsus must be taken on an empty stomach with no more than 4 oz (120 mL) of water, and you must wait at least 30 minutes before eating or taking other medications. This absorption requirement is not optional. It exists because semaglutide has very poor oral bioavailability, around 1%, and food or other liquids dramatically reduce absorption further, as demonstrated by Bucheit and Pamulapati (2020, Drugs).

What the creator appears to omit from the caption, though the transcript is too broken to confirm verbally, includes the following. First, Rybelsus is not a weight loss drug in the Malaysian regulatory context. It is approved for glycemic control in type 2 diabetes. Second, the caption says nothing about gastrointestinal side effects, nausea, vomiting, and diarrhea, which affect a meaningful proportion of users and are the primary reason people discontinue. Third, there is no mention of contraindications, including personal or family history of medullary thyroid carcinoma, which carries a boxed warning in the prescribing information.

What should you actually know?

If you or someone you know has type 2 diabetes and is considering Rybelsus, here is what actually matters beyond the basics this video covers.

• The 30-minute fasting window before taking Rybelsus is non-negotiable for the drug to work properly. Missing this consistently can mean the medication is largely ineffective.
• Rybelsus is not interchangeable with injectable semaglutide (Ozempic). They have different pharmacokinetic profiles, different doses, and different approved indications. Do not assume the same outcomes.
• GLP-1 receptor agonists like semaglutide also have cardiovascular benefits in high-risk patients with type 2 diabetes. Husain et al. (2019, New England Journal of Medicine) demonstrated non-inferiority and potential cardiovascular benefit with oral semaglutide in PIONEER 6, which is relevant for patients with existing heart disease.
• Common side effects, particularly nausea, tend to be worst in the first few weeks and often improve. Starting at a lower dose and titrating up helps most people tolerate the drug better.
• This is a prescription-only medication for a reason. A TikTok video, including this one, is not a substitute for a consultation with a licensed prescriber who can assess whether Rybelsus is appropriate for your specific situation.